Benralizumab 100 mg

BIOLOGICAL3 trials

Sponsors

MedImmune LLC

Conditions

AsthmaPulmonary Disease, Chronic Obstructive

Phase 2

A Phase 2a Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Adults With Asthma

CompletedNCT00783289

MedImmune LLCAsthma

Start: 2008-11-14End: 2009-11-17Updated: 2019-12-27

A Study to Evaluate the Effectiveness of MEDI-563 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT01227278

MedImmune LLCPulmonary Disease, Chronic Obstructive

Start: 2010-11-30End: 2013-07-31Updated: 2016-10-05

Study to Evaluate the Efficacy and Safety of MEDI-563 in Adults With Uncontrolled Asthma

CompletedNCT01238861

MedImmune LLCAsthma

Start: 2010-12-31End: 2013-08-31Updated: 2016-11-17

Related Papers

Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases

Respiratory Research2019-01-1865 citations

Reductions in eosinophil biomarkers by benralizumab in patients with asthma.

2016-01-08131 citations

Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study.

2014-10-08351 citations

Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study.

2014-09-07239 citations